Significant efforts to identify and test more strategies to reduce the autoimmune side effects of immunotherapy, and more specifically intracellular checkpoint inhibitor treatment, are required to unleash the full potential of CD8+ T cells in cancer immunotherapy. This evidence concerns the gene CD8A and cancer.